CN114984116B - Essential oil composition with pain relieving effect and application thereof - Google Patents
Essential oil composition with pain relieving effect and application thereof Download PDFInfo
- Publication number
- CN114984116B CN114984116B CN202210628857.2A CN202210628857A CN114984116B CN 114984116 B CN114984116 B CN 114984116B CN 202210628857 A CN202210628857 A CN 202210628857A CN 114984116 B CN114984116 B CN 114984116B
- Authority
- CN
- China
- Prior art keywords
- essential oil
- parts
- oil composition
- pain
- oil
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000341 volatile oil Substances 0.000 title claims abstract description 333
- 239000000203 mixture Substances 0.000 title claims abstract description 86
- 230000000694 effects Effects 0.000 title claims abstract description 78
- 208000002193 Pain Diseases 0.000 title claims abstract description 60
- 230000036407 pain Effects 0.000 title claims abstract description 60
- 239000002023 wood Substances 0.000 claims abstract description 24
- 244000178870 Lavandula angustifolia Species 0.000 claims abstract description 18
- 235000010663 Lavandula angustifolia Nutrition 0.000 claims abstract description 18
- 239000001102 lavandula vera Substances 0.000 claims abstract description 18
- 235000018219 lavender Nutrition 0.000 claims abstract description 18
- 241001093951 Ailanthus altissima Species 0.000 claims abstract description 17
- 239000003814 drug Substances 0.000 claims abstract description 9
- 244000131316 Panax pseudoginseng Species 0.000 claims description 17
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 claims description 14
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 claims description 14
- 229940116229 borneol Drugs 0.000 claims description 14
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 claims description 14
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 claims description 14
- 235000003181 Panax pseudoginseng Nutrition 0.000 claims description 10
- 241000913745 Spatholobus Species 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 10
- 239000003921 oil Substances 0.000 claims description 9
- 240000000528 Ricinus communis Species 0.000 claims description 8
- 235000004443 Ricinus communis Nutrition 0.000 claims description 8
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims description 7
- 235000003140 Panax quinquefolius Nutrition 0.000 claims description 7
- 235000008434 ginseng Nutrition 0.000 claims description 7
- 235000003261 Artemisia vulgaris Nutrition 0.000 claims description 6
- 240000006891 Artemisia vulgaris Species 0.000 claims description 6
- 235000005979 Citrus limon Nutrition 0.000 claims description 6
- 244000131522 Citrus pyriformis Species 0.000 claims description 6
- 244000246386 Mentha pulegium Species 0.000 claims description 6
- 235000016257 Mentha pulegium Nutrition 0.000 claims description 6
- 235000004357 Mentha x piperita Nutrition 0.000 claims description 6
- 239000010651 grapefruit oil Substances 0.000 claims description 6
- 235000001050 hortel pimenta Nutrition 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 5
- 240000004510 Agastache rugosa Species 0.000 claims description 4
- 238000001256 steam distillation Methods 0.000 claims description 4
- 238000005303 weighing Methods 0.000 claims description 3
- 244000144725 Amygdalus communis Species 0.000 claims 1
- 235000003893 Prunus dulcis var amara Nutrition 0.000 claims 1
- 206010019233 Headaches Diseases 0.000 abstract description 31
- 231100000869 headache Toxicity 0.000 abstract description 29
- 239000002199 base oil Substances 0.000 abstract description 12
- 206010029216 Nervousness Diseases 0.000 abstract description 10
- 210000000988 bone and bone Anatomy 0.000 abstract description 8
- 241000425037 Toona sinensis Species 0.000 abstract description 7
- 206010006002 Bone pain Diseases 0.000 abstract description 5
- 241000212948 Cnidium Species 0.000 abstract description 5
- 208000000112 Myalgia Diseases 0.000 abstract description 5
- 208000013465 muscle pain Diseases 0.000 abstract description 5
- 230000000037 effect on migraine Effects 0.000 abstract description 4
- 231100000331 toxic Toxicity 0.000 abstract description 4
- 230000002588 toxic effect Effects 0.000 abstract description 4
- 241001254604 Angelica pubescens Species 0.000 abstract description 2
- 238000012360 testing method Methods 0.000 description 35
- 208000008035 Back Pain Diseases 0.000 description 25
- 208000024891 symptom Diseases 0.000 description 21
- 230000000052 comparative effect Effects 0.000 description 16
- WTVHAMTYZJGJLJ-UHFFFAOYSA-N (+)-(4S,8R)-8-epi-beta-bisabolol Natural products CC(C)=CCCC(C)C1(O)CCC(C)=CC1 WTVHAMTYZJGJLJ-UHFFFAOYSA-N 0.000 description 14
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 14
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 14
- RGZSQWQPBWRIAQ-LSDHHAIUSA-N alpha-Bisabolol Natural products CC(C)=CCC[C@@](C)(O)[C@@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-LSDHHAIUSA-N 0.000 description 14
- 229940036350 bisabolol Drugs 0.000 description 14
- HHGZABIIYIWLGA-UHFFFAOYSA-N bisabolol Natural products CC1CCC(C(C)(O)CCC=C(C)C)CC1 HHGZABIIYIWLGA-UHFFFAOYSA-N 0.000 description 14
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 14
- 229940031439 squalene Drugs 0.000 description 14
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 14
- RGZSQWQPBWRIAQ-CABCVRRESA-N (-)-alpha-Bisabolol Chemical compound CC(C)=CCC[C@](C)(O)[C@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-CABCVRRESA-N 0.000 description 12
- 238000011835 investigation Methods 0.000 description 12
- 239000004359 castor oil Substances 0.000 description 11
- 235000019438 castor oil Nutrition 0.000 description 11
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 11
- 208000019695 Migraine disease Diseases 0.000 description 9
- 206010028836 Neck pain Diseases 0.000 description 9
- 206010027599 migraine Diseases 0.000 description 9
- 206010028391 Musculoskeletal Pain Diseases 0.000 description 8
- 208000007613 Shoulder Pain Diseases 0.000 description 8
- 235000019198 oils Nutrition 0.000 description 8
- -1 antiinflammatory Substances 0.000 description 7
- 239000012752 auxiliary agent Substances 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 238000003359 percent control normalization Methods 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 238000003825 pressing Methods 0.000 description 6
- 244000018633 Prunus armeniaca Species 0.000 description 5
- 235000009827 Prunus armeniaca Nutrition 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 230000001737 promoting effect Effects 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 235000013399 edible fruits Nutrition 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 229940119170 jojoba wax Drugs 0.000 description 4
- 230000001954 sterilising effect Effects 0.000 description 4
- 239000010497 wheat germ oil Substances 0.000 description 4
- 208000008930 Low Back Pain Diseases 0.000 description 3
- 235000006679 Mentha X verticillata Nutrition 0.000 description 3
- 235000002899 Mentha suaveolens Nutrition 0.000 description 3
- 235000001636 Mentha x rotundifolia Nutrition 0.000 description 3
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 230000003467 diminishing effect Effects 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 210000005036 nerve Anatomy 0.000 description 3
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
- 239000001856 Ethyl cellulose Substances 0.000 description 2
- 240000002505 Pogostemon cablin Species 0.000 description 2
- 235000011751 Pogostemon cablin Nutrition 0.000 description 2
- 229920002385 Sodium hyaluronate Polymers 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 229960001138 acetylsalicylic acid Drugs 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 125000002138 bisabolol group Chemical group 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000013329 compounding Methods 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 229920001249 ethyl cellulose Polymers 0.000 description 2
- 235000019325 ethyl cellulose Nutrition 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000005713 exacerbation Effects 0.000 description 2
- 229960005150 glycerol Drugs 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 229940040145 liniment Drugs 0.000 description 2
- 239000000865 liniment Substances 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 229940010747 sodium hyaluronate Drugs 0.000 description 2
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 239000011732 tocopherol Substances 0.000 description 2
- 229960001295 tocopherol Drugs 0.000 description 2
- 229930003799 tocopherol Natural products 0.000 description 2
- 235000010384 tocopherol Nutrition 0.000 description 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 208000028185 Angioedema Diseases 0.000 description 1
- 206010004716 Binge eating Diseases 0.000 description 1
- 208000032841 Bulimia Diseases 0.000 description 1
- 244000271246 Cedrela sinensis Species 0.000 description 1
- 235000011783 Cedrela sinensis Nutrition 0.000 description 1
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010053155 Epigastric discomfort Diseases 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 208000025047 Non-histaminic angioedema Diseases 0.000 description 1
- 206010034464 Periarthritis Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- HDSBZMRLPLPFLQ-UHFFFAOYSA-N Propylene glycol alginate Chemical compound OC1C(O)C(OC)OC(C(O)=O)C1OC1C(O)C(O)C(C)C(C(=O)OCC(C)O)O1 HDSBZMRLPLPFLQ-UHFFFAOYSA-N 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 206010061481 Renal injury Diseases 0.000 description 1
- BCKXLBQYZLBQEK-KVVVOXFISA-M Sodium oleate Chemical compound [Na+].CCCCCCCC\C=C/CCCCCCCC([O-])=O BCKXLBQYZLBQEK-KVVVOXFISA-M 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 240000007284 Stenochlaena palustris Species 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 1
- 150000001241 acetals Chemical class 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 229940023476 agar Drugs 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 230000003356 anti-rheumatic effect Effects 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 239000003907 antipyretic analgesic agent Substances 0.000 description 1
- 239000003435 antirheumatic agent Substances 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 235000019606 astringent taste Nutrition 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 229940092738 beeswax Drugs 0.000 description 1
- 208000014679 binge eating disease Diseases 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 231100000259 cardiotoxicity Toxicity 0.000 description 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000000249 desinfective effect Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 229940014259 gelatin Drugs 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 239000008169 grapeseed oil Substances 0.000 description 1
- 230000007678 heart toxicity Effects 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 1
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 208000037806 kidney injury Diseases 0.000 description 1
- 210000000629 knee joint Anatomy 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 210000002414 leg Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 201000000585 muscular atrophy Diseases 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- 229920005615 natural polymer Polymers 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 238000000554 physical therapy Methods 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229950008882 polysorbate Drugs 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 235000010409 propane-1,2-diol alginate Nutrition 0.000 description 1
- 239000000770 propane-1,2-diol alginate Substances 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 238000000194 supercritical-fluid extraction Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 238000007514 turning Methods 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/11—Pteridophyta or Filicophyta (ferns)
- A61K36/12—Filicopsida or Pteridopsida
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/234—Cnidium (snowparsley)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/237—Notopterygium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/282—Artemisia, e.g. wormwood or sagebrush
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/285—Aucklandia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/486—Millettia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/489—Sophora, e.g. necklacepod or mamani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/532—Agastache, e.g. giant hyssop
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/534—Mentha (mint)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/58—Meliaceae (Chinaberry or Mahogany family), e.g. Azadirachta (neem)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/736—Prunus, e.g. plum, cherry, peach, apricot or almond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/87—Vitaceae or Ampelidaceae (Vine or Grape family), e.g. wine grapes, muscadine or peppervine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11B—PRODUCING, e.g. BY PRESSING RAW MATERIALS OR BY EXTRACTION FROM WASTE MATERIALS, REFINING OR PRESERVING FATS, FATTY SUBSTANCES, e.g. LANOLIN, FATTY OILS OR WAXES; ESSENTIAL OILS; PERFUMES
- C11B9/00—Essential oils; Perfumes
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11B—PRODUCING, e.g. BY PRESSING RAW MATERIALS OR BY EXTRACTION FROM WASTE MATERIALS, REFINING OR PRESERVING FATS, FATTY SUBSTANCES, e.g. LANOLIN, FATTY OILS OR WAXES; ESSENTIAL OILS; PERFUMES
- C11B9/00—Essential oils; Perfumes
- C11B9/02—Recovery or refining of essential oils from raw materials
- C11B9/027—Recovery of volatiles by distillation or stripping
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pain & Pain Management (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Wood Science & Technology (AREA)
- Rheumatology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention provides an essential oil composition with pain relieving effect and application thereof, wherein the essential oil composition comprises the following components in parts by weight: 1.5 to 5 parts of lavender essential oil, 1 to 5 parts of yam essential oil, 0.5 to 3 parts of wood essential oil, 1 to 5 parts of radix angelicae pubescentis essential oil, 1 to 5 parts of notopterygium root essential oil, 1 to 5 parts of fructus cnidii essential oil, 1 to 2 parts of ailanthus altissima root essential oil and 20 to 50 parts of base oil. The invention reasonably selects the components of lavender essential oil, mount-Chinese yam essential oil, wood essential oil, pubescent angelica essential oil, notopterygium essential oil, cnidium essential oil, chinese toon root essential oil, base oil and the like to cooperate with each other, and the components are carefully modulated according to the theory of traditional Chinese medicine, so that the invention has good effect of relieving bone and muscle pain, also has certain effect on migraine and nervous headache, is safe, has no toxic or side effect, and is suitable for any adult population to use.
Description
Technical Field
The invention relates to the technical field of daily chemical health-care products, in particular to an essential oil composition with pain relieving effect and application thereof.
Background
With the continuous acceleration of modern life rhythm, various bad life habits are generated, such as staying up, sitting for a long time, low head, binge eating and the like, and various skin inflammations, chronic diseases, nervous headache, migraine and various pain problems of bone joints, back, neck, shoulder and waist are generated along with the bad life habits. Among them, the pain problem of the bone joints, back, neck, shoulder and waist is most prominent, if not treated in time, muscular atrophy and skeletal deformation can be caused, not only the health of human body is seriously affected, but also the quality of life is reduced. The analgesic can better relieve the pain of the patient and plays a great role in relieving the pain of the patient. However, at the same time, the great side effects of analgesic drugs are also attracting attention, and aspirin, which is a typical representative of antipyretic analgesic anti-inflammatory drugs, has strong antirheumatic, antiinflammatory, antipyretic and analgesic effects, but aspirin can cause various side effects such as nausea, vomiting, epigastric discomfort, rash, angioneurotic edema, asthma, headache, dizziness, tinnitus, hypopsia, liver injury, kidney injury, heart toxicity and the like.
With the enhancement of health care consciousness of people, more and more people begin to choose essential oil for physical therapy to prevent, relieve or treat certain diseases, such as aromatic therapy popular at home and abroad, has a thousands of centuries of application history. Modern scientific research also proves that certain essential oils have efficacy in potentially damaging lesions, alleviating and alleviating symptoms of disease in humans. However, at present, the domestic essential oil products are mixed with fish and have different quality, hundreds of essential oil varieties for relieving pain can be searched, and many of the essential oil varieties have single effects and cannot be rapidly effective. Therefore, it is necessary to develop an essential oil product which is truly valuable and widely applicable to rapid relief of various pains.
Disclosure of Invention
Aiming at the problems existing in the prior art, the invention provides an essential oil composition with pain relieving effect and application thereof, the essential oil composition has reasonable compatibility, obvious bone and muscle pain relieving effect, certain effect on migraine and nerve headache, safety and no toxic or side effect. The technical scheme of the invention is as follows:
in a first aspect, the present invention provides an essential oil composition having pain relief effect, comprising, in parts by weight: 1.5 to 5 parts of lavender essential oil, 1 to 5 parts of yam essential oil, 0.5 to 3 parts of wood essential oil, 1 to 5 parts of radix angelicae pubescentis essential oil, 1 to 5 parts of notopterygium root essential oil, 1 to 5 parts of fructus cnidii essential oil, 1 to 2 parts of ailanthus altissima root essential oil and 20 to 50 parts of base oil.
Preferably, the essential oil composition further comprises: 0.1 to 1 part of suberect spatholobus stem essential oil, 1 to 3 parts of pseudo-ginseng essential oil and 0.1 to 1 part of ginseng essential oil.
Preferably, the essential oil composition further comprises: 0.1 to 1 part of borneol essential oil and/or 0.1 to 1 part of peppermint essential oil.
Further, the essential oil composition further comprises: 1 to 5 parts of lemon essential oil, 1 to 5 parts of mugwort essential oil and 0.5 to 3 parts of patchouli essential oil.
Further, the essential oil composition further comprises: 1-5 parts of kuh-seng essential oil and 3-5 parts of rhizoma cibotii essential oil.
Further, the essential oil composition further comprises: 1 to 5 parts of kuh-seng essential oil, 1 to 5 parts of bitter apricot seed essential oil and 1 to 5 parts of grapefruit oil.
Further, the base oil is castor oil.
Further, the essential oil composition further comprises 0.1-5 parts of auxiliary agent according to parts by weight.
Further, the auxiliary agent is selected from one or more of the following groups: bisabolol, tocopherol, glycerol, sodium hyaluronate, and squalene.
Preferably, the auxiliary agent is bisabolol and squalene, and the mass ratio is 2: 1.
Preferably, the essential oil composition comprises the following components in parts by weight: 3 parts of lavender essential oil, 3 parts of Mount-line essential oil, 1 part of wood essential oil, 5 parts of radix angelicae pubescentis essential oil, 5 parts of notopterygium root essential oil, 3 parts of fructus cnidii essential oil, 1 part of ailanthus altissima root essential oil, 0.5 part of suberect spatholobus stem essential oil, 3 parts of pseudo-ginseng essential oil, 1 part of borneol essential oil, 5 parts of lemon essential oil, 5 parts of mugwort leaf essential oil, 2 parts of wrinkled gianthyssop essential oil, 30 parts of castor bean oil, 1 part of bisabolol and 0.5 part of squalene.
Preferably, the essential oil composition comprises the following components in parts by weight: 2 parts of lavender essential oil, 5 parts of Mount-line essential oil, 1 part of wood essential oil, 5 parts of radix angelicae pubescentis essential oil, 5 parts of notopterygium root essential oil, 5 parts of fructus cnidii essential oil, 2 parts of ailanthus altissima root essential oil, 0.5 part of suberect spatholobus stem essential oil, 3 parts of pseudo-ginseng essential oil, 0.5 part of borneol essential oil, 5 parts of kuh-seng essential oil, 5 parts of rhizoma cibotii essential oil, 30 parts of castor bean oil, 1 part of bisabolol and 0.5 part of squalene.
Preferably, the essential oil composition comprises the following components in parts by weight: 2 parts of lavender essential oil, 2 parts of Mount-Chinese yam essential oil, 0.5 part of wood essential oil, 1 part of radix angelicae pubescentis essential oil, 1 part of notopterygium root essential oil, 1 part of fructus cnidii essential oil, 1 part of ailanthus altissima root essential oil, 0.5 part of ginseng essential oil, 0.1 part of borneol essential oil and 0.3 part of peppermint essential oil, 1 part of kuh-seng essential oil, 1 part of bitter apricot seed essential oil, 1 part of grapefruit oil, 50 parts of castor oil, 1 part of bisabolol and 0.5 part of squalene.
In a second aspect, the present invention provides a method for preparing the above essential oil composition with pain relieving effect, comprising the steps of: preparing the single essential oils by steam distillation, weighing the single essential oils and the base oil according to the formula amount, and mixing uniformly.
In a third aspect, the present invention provides a medicament having pain relief effect, comprising the above-mentioned essential oil composition.
Further, the medicament also comprises pharmaceutically acceptable auxiliary materials.
Further, the pharmaceutical dosage form is a paste, emulsion, gel, liniment or patch.
The invention reasonably selects the components of lavender essential oil, mount-Chinese yam essential oil, wood essential oil, pubescent angelica essential oil, notopterygium essential oil, cnidium essential oil, chinese toon root essential oil, base oil and the like to cooperate with each other, and the components are carefully modulated according to the theory of traditional Chinese medicine, so that the invention has good effect of relieving bone and muscle pain, also has certain effect on migraine and nervous headache, is safe, has no toxic or side effect, and is suitable for any adult population to use.
Detailed Description
Embodiments of the present invention will be described in detail below with reference to examples, but it will be understood by those skilled in the art that the following examples are only for illustrating the present invention and should not be construed as limiting the scope of the present invention. The specific conditions are not noted in the examples and are carried out according to conventional conditions or conditions recommended by the manufacturer. The reagents or apparatus used were conventional products commercially available without the manufacturer's attention.
The essential oil is volatile aromatic substance extracted from flowers, leaves, stems, roots or fruits of plants by steam distillation, supercritical extraction, extrusion, cold soaking or solvent extraction, and most of the essential oil has single direct use, limited efficacy and is easy to cause irritation, allergy and other phenomena. The invention is prepared by mutually and cooperatively combining the components of lavender essential oil, mount-Chinese yam essential oil, wood essential oil, radix angelicae pubescentis essential oil, notopterygium essential oil, fructus cnidii essential oil, chinese toon root essential oil, basic oil and the like according to the theory of traditional Chinese medicine, has good effect of relieving bone and muscle pain, also has certain effect on migraine and nerve headache, and is safe and free from toxic and side effects.
To achieve the object, a first aspect of the present invention provides an essential oil composition having pain relieving effect, comprising, in parts by weight: 1.5 to 5 parts of lavender essential oil, 1 to 5 parts of yam essential oil, 0.5 to 3 parts of wood essential oil, 1 to 5 parts of radix angelicae pubescentis essential oil, 1 to 5 parts of notopterygium root essential oil, 1 to 5 parts of fructus cnidii essential oil, 1 to 2 parts of ailanthus altissima root essential oil and 20 to 50 parts of base oil.
According to the invention, the lavender essential oil has the effects of relieving pain, resisting depression, disinfecting, sterilizing, relieving congestion and swelling, reducing blood pressure, calming and recovering the essence, the lavender essential oil is matched with the yam essential oil with the effects of removing blood stasis and relieving swelling, the radix angelicae pubescentis essential oil with the effects of resisting inflammation and relieving pain can have good effects of relieving bone and muscle pain, the addition of the notopterygium root essential oil and the fructus cnidii essential oil has good effects of dispelling wind and removing dampness, sterilizing and diminishing inflammation, and the effects of relieving pain of the compound essential oils are further enhanced by the aid of the toona sinensis root essential oil and the wood essential oil. Wherein, the Chinese toon root is a medicine for clearing heat and drying dampness, and has the effects of astringing and inducing astringency. The costustoot has the effects of strengthening the spleen and promoting digestion, and can help the human body to dredge the whole body qi movement, but simultaneously contains a plurality of volatile oil, ether alcohols and other components, and the components have the effects of sterilizing and diminishing inflammation. In the invention, the use of the ailanthus altissima root essential oil and the wood essential oil can consolidate the efficacies of the above essential oils.
In order to further enhance the pain relief effect, in the present invention, the essential oil composition further comprises: 0.1 to 1 part of suberect spatholobus stem essential oil, 1 to 3 parts of pseudo-ginseng essential oil and 0.1 to 1 part of ginseng essential oil.
In the invention, the spatholobus stem and the pseudo-ginseng have the effects of promoting blood circulation and removing obstruction in collaterals, and have good effects of promoting blood circulation and relieving pain when being compounded with the climbing fern for bones and muscles. And for nervous headache and migraine, proper amount of ginseng is better.
Preferably, the essential oil composition of the present invention further comprises: 0.1 to 1 part of borneol essential oil and/or 0.1 to 1 part of peppermint essential oil. Wherein, the borneol essential oil has excellent transdermal function, is a good permeation promoter, and has the function of promoting blood circulation. The penetration promoting function of the mint essential oil is inferior to that of borneol essential oil, but the mint essential oil has good efficacy on headache, nerve disorder and spasm, so the mint essential oil is compounded for migraine and nervous headache.
In the present invention, in order to better relieve the low back pain, the essential oil composition further comprises: 1 to 5 parts of lemon essential oil, 1 to 5 parts of mugwort essential oil and 0.5 to 3 parts of patchouli essential oil.
And in order to better relieve back, neck and shoulder pain, the essential oil composition further comprises: 1-5 parts of kuh-seng essential oil and 3-5 parts of rhizoma cibotii essential oil.
And in order to relieve migraine and nervous headache, the essential oil composition further comprises: 1 to 5 parts of kuh-seng essential oil, 1 to 5 parts of bitter apricot seed essential oil and 1 to 5 parts of grapefruit oil.
In the present invention, the base oil is castor oil. The castor oil has good convergence efficacy, can relieve pain and itching, and can better play the effect of relieving pain by being compounded with the essential oil component. However, the base oil is not limited to castor oil, and any of grape seed oil, wheat germ oil, olive oil, jojoba oil and the like may be used as the base oil of the present invention.
In the invention, the essential oil composition further comprises 0.1-5 parts of auxiliary agent according to parts by weight.
The auxiliary agent is selected from one or more of the following groups: bisabolol, tocopherol, glycerol, sodium hyaluronate, and squalene.
Preferably, the auxiliary agent is bisabolol and squalene which are compounded according to the mass ratio of 2:1. Bisabolol is an active ingredient extracted from spring Huang Juli, has good solubilizing property, is used as a solubilizer of a mixed essential oil component in the invention, has the effects of sterilizing, diminishing inflammation, resisting irritation, repairing and the like, and can enhance the pain relieving effect of an essential oil composition when being matched with squalene.
The essential oil composition of the invention is prepared from the following components in parts by weight: 3 parts of lavender essential oil, 3 parts of Mount-line essential oil, 1 part of wood essential oil, 5 parts of radix angelicae pubescentis essential oil, 5 parts of notopterygium root essential oil, 3 parts of fructus cnidii essential oil, 1 part of ailanthus altissima root essential oil, 0.5 part of suberect spatholobus stem essential oil, 3 parts of pseudo-ginseng essential oil, 1 part of borneol essential oil, 5 parts of lemon essential oil, 5 parts of mugwort leaf essential oil, 2 parts of wrinkled gianthyssop essential oil, 30 parts of castor bean oil, 1 part of bisabolol and 0.5 part of squalene. The essential oil composition obtained by the compound formula is mainly used for relieving pain in the waist and legs.
Another preferable compounding mode of the essential oil composition of the invention comprises the following components in parts by weight: 2 parts of lavender essential oil, 5 parts of Mount-line essential oil, 1 part of wood essential oil, 5 parts of radix angelicae pubescentis essential oil, 5 parts of notopterygium root essential oil, 5 parts of fructus cnidii essential oil, 2 parts of ailanthus altissima root essential oil, 0.5 part of suberect spatholobus stem essential oil, 3 parts of pseudo-ginseng essential oil, 0.5 part of borneol essential oil, 5 parts of kuh-seng essential oil, 5 parts of rhizoma cibotii essential oil, 30 parts of castor bean oil, 1 part of bisabolol and 0.5 part of squalene. The essential oil composition obtained by the compound formula is mainly used for relieving back, neck and shoulder pain.
Another preferable compounding mode of the essential oil composition of the invention comprises the following components in parts by weight: 2 parts of lavender essential oil, 2 parts of Mount-Chinese yam essential oil, 0.5 part of wood essential oil, 1 part of radix angelicae pubescentis essential oil, 1 part of notopterygium root essential oil, 1 part of fructus cnidii essential oil, 1 part of ailanthus altissima root essential oil, 0.5 part of ginseng essential oil, 0.1 part of borneol essential oil and 0.3 part of peppermint essential oil, 1 part of kuh-seng essential oil, 1 part of bitter apricot seed essential oil, 1 part of grapefruit oil, 50 parts of castor oil, 1 part of bisabolol and 0.5 part of squalene. The essential oil composition obtained by the compound formula is mainly used for relieving migraine and nervous headache.
The second aspect of the present invention provides a method for preparing the above essential oil composition with pain relieving effect, comprising the following steps: preparing the single essential oils by steam distillation, weighing the single essential oils and the base oil according to the formula amount, and mixing uniformly.
In the present invention, the individual essential oils may be obtained by a commercially available method.
In a preferred preparation method of the invention, the base oil and the auxiliary agent are mixed uniformly, and then each single essential oil is added for further uniform mixing. The mixing means may be stirring, rolling, turning, shaking, etc.
The essential oil composition provided by the invention is simple in use method, and can be directly smeared on painful parts of a body, and the operation effects of pressing, massaging, acupoint pressing and the like are better.
In a third aspect, the present invention provides a medicament having pain relieving effect, comprising the above-mentioned essential oil composition.
In the invention, the medicine also comprises pharmaceutically acceptable auxiliary materials. Depending on the different pharmaceutical dosage forms: different auxiliary materials are adopted for the ointment, the emulsion, the gel, the liniment or the patch. The common auxiliary materials of the ointment are as follows: vaseline, liquid paraffin, lanolin, beeswax, animal oil, vegetable oil, glyceryl monostearate, stearyl alcohol, etc. and their mixture. The common auxiliary materials of the emulsion are emulsifying agents. The common auxiliary materials of the emulsion are as follows: lipophilic emulsifying agent such as cetyl alcohol and cholesterol, nonionic emulsifying agent such as polysorbate and sorbitan fatty acid, and sodium oleate. Common auxiliary materials of the gel agent include: water-soluble polymers such as methylcellulose, hydroxypropyl methylcellulose phthalate, hydroxypropyl methylcellulose succinate, hydroxymethyl ethylcellulose, carboxymethyl ethylcellulose, sodium carboxymethyl cellulose, hydroxyethyl cellulose, cellulose acetate phthalate, and the like; polyethylene glycol, polyvinyl alcohol, polyvinylpyrrolidone, polyvinyl acetal diethylamino-misplaced acid ester, aminoalkyl methacrylate copolymer-E, aminoalkyl methacrylate copolymer-RS, methacrylic acid copolymer-L, methacrylic acid copolymer-LD, methacrylic acid copolymer-S, carboxyvinyl polymer and the like; natural polymers such as acacia, sodium alginate, propylene glycol alginate, agar, gelatin, and xanthan gum, and saccharides.
The technical scheme provided by the invention is further described below by combining examples and comparative examples.
Example 1
The embodiment provides an essential oil composition with pain relieving effect, which comprises the following components in parts by weight: the composition comprises the following components in parts by weight: 3 parts of lavender essential oil, 3 parts of Mount-Chinese yam essential oil, 1 part of wood essential oil, 5 parts of radix angelicae pubescentis essential oil, 5 parts of notopterygium root essential oil, 3 parts of cnidium fruit essential oil, 1 part of ailanthus altissima root essential oil and 30 parts of castor bean oil.
Example 2
This example provides an essential oil composition with pain relief effect, which differs from example 1 in that: also comprises 0.5 part of spatholobus stem essential oil and 3 parts of pseudo-ginseng essential oil.
Example 3
This example provides an essential oil composition with pain relief effect, which differs from example 2 in that: also comprises 1 part of borneol essential oil.
Example 4
This example provides an essential oil composition with pain relief effect, which differs from example 3 in that: also comprises 5 parts of lemon essential oil, 5 parts of mugwort essential oil and 2 parts of wrinkled giant hyssop essential oil.
Example 5
This example provides an essential oil composition with pain relief effect, which differs from example 4 in that: also comprises 1 part of bisabolol and 0.5 part of squalene.
Example 6
The embodiment provides an essential oil composition with pain relieving effect, which comprises the following components in parts by weight: 2 parts of lavender essential oil, 5 parts of Mount-Chinese yam essential oil, 1 part of wood essential oil, 5 parts of radix angelicae pubescentis essential oil, 5 parts of notopterygium root essential oil, 5 parts of cnidium fruit essential oil, 2 parts of ailanthus altissima root essential oil and 30 parts of castor bean oil.
Example 7
This example provides an essential oil composition with pain relief effect, which differs from example 6 in that: also comprises 0.5 part of spatholobus stem essential oil and 3 parts of pseudo-ginseng essential oil.
Example 8
This example provides an essential oil composition with pain relief effect, which differs from example 7 in that: also comprises 0.5 part of borneol essential oil.
Example 9
This example provides an essential oil composition with pain relief effect, which differs from example 8 in that: also comprises 5 parts of kuh-seng essential oil and 5 parts of rhizoma cibotii essential oil.
Example 10
This example provides an essential oil composition with pain relief effect, which differs from example 9 in that: also comprises 1 part of bisabolol and 0.5 part of squalene.
Example 11
The embodiment provides an essential oil composition with pain relieving effect, which comprises the following components in parts by weight: 2 parts of lavender essential oil, 2 parts of Mount-Chinese yam essential oil, 0.5 part of wood essential oil, 1 part of radix angelicae pubescentis essential oil, 1 part of notopterygium root essential oil, 1 part of cnidium fruit essential oil, 1 part of ailanthus altissima root essential oil and 50 parts of castor bean oil.
Example 12
This example provides an essential oil composition with pain relief effect, which differs from example 11 in that: also comprises 0.5 part of ginseng essential oil.
Example 13
This example provides an essential oil composition with pain relief effect, which differs from example 12 in that: also comprises 0.1 part of borneol essential oil and 0.3 part of peppermint essential oil.
Example 14
This example provides an essential oil composition with pain relief effect, which differs from example 13 in that: also comprises 1 part of kuh-seng essential oil, 1 part of bitter apricot seed essential oil and 1 part of grapefruit oil.
Example 15
This example provides an essential oil composition with pain relief effect, which differs from example 14 in that: also comprises 1 part of bisabolol and 0.5 part of squalene.
Comparative example 1
This comparative example provides an essential oil composition having pain relief efficacy, differing from example 1 in that: the Chinese toon root essential oil and the wood essential oil are not contained.
Comparative example 2
This comparative example provides an essential oil composition having pain relief efficacy, differing from example 1 in that: the castor oil was replaced with 15 parts of wheat germ oil and 15 parts of jojoba oil.
Comparative example 3
This comparative example provides an essential oil composition having pain relief efficacy, differing from example 6 in that: the Chinese toon root essential oil and the wood essential oil are not contained.
Comparative example 4
This comparative example provides an essential oil composition having pain relief efficacy, differing from example 6 in that: the castor oil was replaced with 15 parts of wheat germ oil and 15 parts of jojoba oil.
Comparative example 5
This comparative example provides an essential oil composition having pain relief efficacy, differing from example 11 in that: the Chinese toon root essential oil and the wood essential oil are not contained.
Comparative example 6
This comparative example provides an essential oil composition having pain relief efficacy, differing from example 11 in that: the castor oil was replaced with 25 parts of wheat germ oil and 25 parts of jojoba oil.
First stage clinical evaluation
1) Investigation of relief efficacy against Low back pain
35 male subjects and 35 female subjects with ages of 30-65 were randomly selected, and the male subjects and female subjects were randomly divided into 7 groups, respectively using the essential oil compositions of examples 1-5 (corresponding to test groups 1-5) and comparative examples 1-2 (corresponding to control groups 1-2), the male and female proportions of each group were also 1:1, and these patients had pain symptoms caused by different degrees of lumbar injuries, and the subjects repeatedly applied the essential oil composition 3 times a day and a night to lumbar pain parts, each time for 3-5 mL, and were used for 4 weeks in combination with 10min massage or pressing to promote absorption. And (3) judging the effect: and (3) curing: the symptoms of the lumbar pain completely disappear; the effect is shown: at least 80% resolution of the symptoms of lumbar pain; the method is effective: the symptoms of the lumbar pain subside by 40 to 60 percent; invalidation: there was no change or exacerbation of the symptoms of lumbar pain. The results are shown in Table 1:
table 1 results of investigation of relief efficacy against lumbar pain
As can be seen from the data in table 1, the essential oil composition of test group 5 has the best effect of relieving the lumbar pain, the total effective rate can reach 100%, and then the total effective rate can reach 90% in test group 3 and test group 4. The control group 1 removes the ailanthus altissima essential oil and the wood essential oil, and the number of significant effects is obviously reduced. 2) Investigation of relief efficacy against back, neck and shoulder pain
Test methods were the same as 1), and test groups 6 to 10 (corresponding to examples 6 to 10) and control groups 3 to 4 (corresponding to comparative examples 3 to 4) were set. The results are shown in Table 2:
table 2 results of investigation of relief efficacy against back, neck and shoulder pain
| Group of | Headcount of people | The number of people healed | Number of people with obvious effect | The effective number of people | Invalid number of people | The total effective rate is% |
| Test group 6 | 10 | 3 | 4 | 2 | 1 | 90％ |
| Test group 7 | 10 | 4 | 4 | 1 | 1 | 90％ |
| Test group 8 | 10 | 4 | 4 | 2 | 0 | 100％ |
| Test group 9 | 10 | 6 | 3 | 0 | 1 | 90％ |
| Test group 10 | 10 | 6 | 4 | 0 | 0 | 100％ |
| Control group 3 | 10 | 0 | 3 | 2 | 5 | 50％ |
| Control group 4 | 10 | 0 | 6 | 2 | 2 | 80％ |
As can be seen from the data in table 2, the essential oil composition of test group 10 has the best soothing effect on back, neck and shoulder pain, the total effective rate can reach 100%, and the cure rate is the highest and reaches 60%. Secondly, in test group 9, the total effective rate can reach 90 percent, and the cure rate can also reach 60 percent. The total effective rate of the test group 8 reaches 100%, and the cure rate can also reach 40%. The control group 3 removes the ailanthus altissima essential oil and the wood essential oil, the total effective rate is only 50 percent, the cure rate is 0, and the number of significant effects is also reduced. After the castor oil is replaced by the control group 4, the cure rate is 0 and the total effective rate is also reduced although the number of significant persons is increased.
3) Investigation of relief efficacy against headache
35 male subjects and 35 female subjects were randomly selected, the ages were 30-65 years, the male subjects and female subjects were randomly divided into 7 groups, the essential oil compositions of examples 11-15 (corresponding to test groups 11-15) and comparative examples 5-6 (corresponding to control groups 5-6) were used respectively, the male and female proportions of each group were also 1:1, these patients had migraine or nervous headache, the subjects repeatedly applied the essential oil composition 2 times per night at the headache site, each time was 0.5-1 mL, and 5min massage or pressing was used in combination to promote absorption for 2 weeks. And (3) judging the effect: and (3) curing: headache symptoms completely disappeared; the effect is shown: at least 80% regression of headache symptoms; the method is effective: headache symptom is resolved by 40 to 60 percent; invalidation: the headache symptoms are unchanged or aggravated. The results are shown in Table 3:
table 3 results of investigation of relief efficacy against headache
| Group of | Headcount of people | The number of people healed | Number of people with obvious effect | The effective number of people | Invalid number of people | The total effective rate is% |
| Test group 11 | 10 | 0 | 5 | 3 | 2 | 80％ |
| Test group 12 | 10 | 2 | 4 | 2 | 2 | 80％ |
| Test group 13 | 10 | 3 | 4 | 2 | 1 | 90％ |
| Test group 14 | 10 | 6 | 3 | 1 | 0 | 100％ |
| Test group 15 | 10 | 8 | 2 | 0 | 0 | 100％ |
| Control group 5 | 10 | 0 | 4 | 3 | 3 | 70％ |
| Control group6 | 10 | 0 | 5 | 3 | 2 | 80％ |
As can be seen primarily from the data in table 3, the essential oil composition of test group 15 has the best soothing effect on head pain, the total effective rate can reach 100%, and the cure rate is the highest, reaching 80%. Secondly, the test group 14 has the total effective rate of 100 percent and the cure rate of 60 percent. The total effective rate of the test groups 11 to 13 can reach more than 80 percent. The control group 5 removes the ailanthus altissima essential oil and the wood essential oil, the total effective rate can reach 70 percent, and the number of significant effects is slightly reduced. After the castor oil replacement, control group 4 had not changed from test group 11.
Second phase clinical evaluation
(1) Investigation of relief efficacy against Low back pain
50 male subjects and 50 female subjects with ages between 30 and 65 were randomly selected, and were randomly divided into 2 groups, and the essential oil compositions of example 5 (corresponding to test group I) and example 10 (corresponding to control group I) in CN201910005254.5 were respectively used, wherein the ratio of male and female in each group was 1:1, and the patients had pain caused by waist injuries of different degrees, and the subjects repeatedly applied the essential oil compositions 3 times a day and 3-5 mL each time at the waist pain part, and the subjects were continuously used for 4 weeks in combination with 10min massage or pressing to promote absorption. And (3) judging the effect: and (3) curing: the symptoms of the lumbar pain completely disappear; the effect is shown: at least 80% resolution of the symptoms of lumbar pain; the method is effective: the symptoms of the lumbar pain subside by 40 to 60 percent; invalidation: there was no change or exacerbation of the symptoms of lumbar pain. The results are shown in Table 4:
table 4 results of investigation of relief efficacy against lumbar pain
| Group of | Headcount of people | The number of people healed | Number of people with obvious effect | The effective number of people | Invalid number of people | The total effective rate is% |
| Test group I | 50 | 17 | 24 | 8 | 1 | 98％ |
| Control group I | 50 | 11 | 18 | 16 | 5 | 90％ |
As can be seen from the data in table 4, the essential oil composition of the test group I has remarkable relief effect on lumbar pain, and the total effective rate reaches 98%, which is better than that of the control group I.
(2) Investigation of relief efficacy against back, neck and shoulder pain
Test method was the same as (1), and test group II (corresponding to example 10) and control group II (corresponding to example 9 in CN 201910005254.5) were set. The results are shown in Table 5:
table 5 results of investigation of relief efficacy against back, neck and shoulder pain
| Group of | Headcount of people | The number of people healed | Number of people with obvious effect | The effective number of people | Invalid number of people | The total effective rate is% |
| Test group II | 50 | 39 | 11 | 0 | 0 | 100％ |
| Control group II | 50 | 24 | 10 | 5 | 11 | 78％ |
As can be seen from the data in table 5, the essential oil composition of test group II has remarkable effect of relieving back and neck and shoulder pain, and the total effective rate reaches 100%, which is better than that of control group II.
(3) Investigation of relief efficacy against headache
50 male subjects and 50 female subjects with ages between 30 and 65 were randomly selected, and the male subjects and female subjects were randomly divided into 2 groups, and the essential oil compositions of example 15 (corresponding to test group III) and CN201911276697.4 (corresponding to control group III) were used respectively, the ratio of male and female in each group was 1:1, and these patients had migraine or nervous headache, and the subjects repeatedly applied the essential oil composition 2 times per night at the headache part, each time by 0.5 to 1mL, and the subjects were continuously used for 2 weeks in combination with 5min massage or pressing to promote absorption. And (3) judging the effect: and (3) curing: headache symptoms completely disappeared; the effect is shown: at least 80% regression of headache symptoms; the method is effective: headache symptom is resolved by 40 to 60 percent; invalidation: the headache symptoms are unchanged or aggravated. The results are shown in Table 6:
table 6 results of investigation of relief efficacy against headache
| Group of | Headcount of people | The number of people healed | Number of people with obvious effect | The effective number of people | Invalid number of people | The total effective rate is% |
| Test group III | 50 | 45 | 2 | 0 | 3 | 90％ |
| Control group III | 50 | 34 | 4 | 11 | 1 | 98％ |
Note that: among the null population in test group III, 1 was allergic to essential oil odor and was discarded after 1 day of use.
As can be seen from the data in table 6, the essential oil composition of test group III has a remarkable soothing effect on head pain, and the total effective rate reaches 90%. Although the total effective rate of the control group III is higher than that of the test group III, the cure rate and the obvious efficiency of the test group III are far higher than those of the control group III.
Typical case
In case one, zhao Mou, women, doctors and lumbar diseases are as long as 7 years, lumbar surgery is performed once, lumbar pain is caused for more than 1 year after operation, and the essential oil of the embodiment 5 of the invention is used for about 1 month, so that the symptoms of lumbar pain are obviously improved.
In case two, han Mou, men and IT engineers work in front of computers for a long time, have serious cervical pain and scapulohumeral periarthritis, have intermittent disease for 3 years, and use the essential oil of the embodiment 10 of the invention for about 2 weeks, so that the pain of the shoulder and neck disappears.
Cases three and Ding Mou, men, security, had premonitory migraine for up to 10 years, and the essential oil of example 15 of the invention was used for about 3 months, so that the symptoms of migraine were significantly reduced.
In cases four and Xia Mou, women, athletes, and knee joints were injured, and pain was lost about 3 days after the essential oil of example 5 of the present invention was used.
Cases five and Cao Mou, women, chefs, had nervous headache for up to 5 years, and the headache symptoms disappeared about 1 month after using the essential oil of example 15 of the present invention.
The foregoing examples illustrate only a few embodiments of the invention and are described in detail herein without thereby limiting the scope of the invention. It should be noted that it will be apparent to those skilled in the art that several variations and modifications can be made without departing from the spirit of the invention, which are all within the scope of the invention. Accordingly, the scope of protection of the present invention is to be determined by the appended claims.
Claims (8)
1. An essential oil composition having pain relief effect, characterized in that: the components are as follows by weight: 1.5-5 parts of lavender essential oil, 1-5 parts of yam essential oil, 0.5-3 parts of wood essential oil, 1-5 parts of radix angelicae pubescentis essential oil, 1-5 parts of notopterygium root essential oil, 1-5 parts of fructus cnidii essential oil, 1-2 parts of ailanthus altissima root essential oil and 20-50 parts of castor bean oil.
2. An essential oil composition having pain relief efficacy as claimed in claim 1, wherein: the essential oil composition further comprises: 0.1-1 part of suberect spatholobus stem essential oil, 1-3 parts of pseudo-ginseng essential oil and 0.1-1 part of ginseng essential oil.
3. An essential oil composition having pain relieving effect according to claim 1 or 2, characterized in that: the essential oil composition further comprises: 0.1-1 part of borneol essential oil and/or 0.1-1 part of peppermint essential oil.
4. An essential oil composition having pain relief efficacy according to claim 3, wherein: the essential oil composition further comprises: 1-5 parts of lemon essential oil, 1-5 parts of mugwort essential oil and 0.5-3 parts of wrinkled gianthyssop essential oil.
5. An essential oil composition having pain relief efficacy according to claim 3, wherein: the essential oil composition further comprises: 1-5 parts of kuh-seng essential oil and 3-5 parts of rhizoma cibotii essential oil.
6. An essential oil composition having pain relief efficacy according to claim 3, wherein: the essential oil composition further comprises: 1-5 parts of kuh-seng essential oil, 1-5 parts of bitter almond essential oil and 1-5 parts of grapefruit oil.
7. The method for preparing the essential oil composition with pain relieving effect according to any one of claims 1 to 6, which is characterized in that: the method comprises the following steps: preparing essential oil by steam distillation, weighing the components according to the formula, and mixing uniformly.
8. A medicament having pain relief efficacy, characterized in that: an essential oil composition according to any one of claims 1 to 6.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210628857.2A CN114984116B (en) | 2022-06-02 | 2022-06-02 | Essential oil composition with pain relieving effect and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210628857.2A CN114984116B (en) | 2022-06-02 | 2022-06-02 | Essential oil composition with pain relieving effect and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN114984116A CN114984116A (en) | 2022-09-02 |
| CN114984116B true CN114984116B (en) | 2024-03-26 |
Family
ID=83031968
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210628857.2A Active CN114984116B (en) | 2022-06-02 | 2022-06-02 | Essential oil composition with pain relieving effect and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114984116B (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107184502A (en) * | 2017-04-21 | 2017-09-22 | 钦州学院 | A kind of medicinal lipstick and preparation method thereof |
| CN109364226A (en) * | 2018-11-13 | 2019-02-22 | 湖北立天生物工程有限公司 | A kind of active relaxing muscles and tendons of moisturizing is releived the ancient method plants essential oil ached and preparation method |
| CN109432174A (en) * | 2019-01-03 | 2019-03-08 | 广州中医药大学(广州中医药研究院) | One kind relieving pain compound essential oil and the preparation method and application thereof |
| CN110170012A (en) * | 2019-07-11 | 2019-08-27 | 江西中医药大学 | Compound essential oil and its preparation method and application and pharmaceutical preparation |
-
2022
- 2022-06-02 CN CN202210628857.2A patent/CN114984116B/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107184502A (en) * | 2017-04-21 | 2017-09-22 | 钦州学院 | A kind of medicinal lipstick and preparation method thereof |
| CN109364226A (en) * | 2018-11-13 | 2019-02-22 | 湖北立天生物工程有限公司 | A kind of active relaxing muscles and tendons of moisturizing is releived the ancient method plants essential oil ached and preparation method |
| CN109432174A (en) * | 2019-01-03 | 2019-03-08 | 广州中医药大学(广州中医药研究院) | One kind relieving pain compound essential oil and the preparation method and application thereof |
| CN110170012A (en) * | 2019-07-11 | 2019-08-27 | 江西中医药大学 | Compound essential oil and its preparation method and application and pharmaceutical preparation |
Also Published As
| Publication number | Publication date |
|---|---|
| CN114984116A (en) | 2022-09-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103520654A (en) | Chinese medicine composition for treating knee osteoarthritis and preparation method of Chinese medicine composition | |
| EP1196183B1 (en) | Oregano-based therapeutic composition | |
| CN108175795A (en) | A kind of plaster | |
| Chatawatee et al. | Effectiveness of knee acupressure along with herbal knee poultice for knee osteoarthritis treatment: A pilot pre-post clinical study | |
| DE202008002953U1 (en) | Chinese herbal recipes for the treatment of musculoskeletal disorders in humans and animals | |
| CN114984116B (en) | Essential oil composition with pain relieving effect and application thereof | |
| CN103784550B (en) | For Chinese medicine composition and the preparation thereof of swelling and pain relieving | |
| CN103550540B (en) | Pharmaceutical composition for preventing and treating cervical spondylosis and lumbar spondylosis | |
| CN111729015A (en) | A drug for adjuvant treatment of knee osteoarthritis | |
| CN105999105A (en) | Traditional Chinese medicine composition for treating bedsores and diabetic ulcers and preparation method thereof | |
| CN105796447B (en) | A kind of Yao medicine bath shower cream and preparation method thereof | |
| CN103751708A (en) | Traditional Chinese medicine external preparation for treating varix of lower limb and preparation method thereof | |
| CN1034053C (en) | The preparation method of Musk Shuhuojing | |
| CN103860676B (en) | A kind of Chinese medicine for external application for the treatment of lumbar muscle strain and preparation method thereof | |
| CN114886979A (en) | Medicine for treating skin disease and its preparing method | |
| CN117731712B (en) | Production method of traditional Chinese medicine tincture for promoting blood circulation and relaxing tendons | |
| Lukubye et al. | Traditional uses, ethnopharmacology, antibacterial and antiparasitic activities of Symphonia spp | |
| CN104971286A (en) | Traditional Chinese medicine composition for treating shoulder, waist and leg discomfort | |
| CN111419924A (en) | A topical Chinese medicinal composition for treating various muscle and bone diseases, and its preparation device | |
| CN110934947A (en) | Traditional Chinese medicine ointment with effects of relieving swelling and pain and preparation method | |
| CN104606455B (en) | Medicament for treating lumbar muscle strain | |
| CN113577166B (en) | Medicinal oil and preparation method thereof | |
| CN109908298A (en) | A kind of bone fracture bruise external preparation and preparation method thereof | |
| CN105412395A (en) | Traditional Chinese medicine composition for treating hyperostosis and preparation method thereof | |
| CN105832618A (en) | Bath salt capable of treating dermatosis and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |